JP2015501636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501636A5 JP2015501636A5 JP2014541370A JP2014541370A JP2015501636A5 JP 2015501636 A5 JP2015501636 A5 JP 2015501636A5 JP 2014541370 A JP2014541370 A JP 2014541370A JP 2014541370 A JP2014541370 A JP 2014541370A JP 2015501636 A5 JP2015501636 A5 JP 2015501636A5
- Authority
- JP
- Japan
- Prior art keywords
- thermostable luciferase
- granzyme
- circular permutation
- polynucleotide
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060001084 Luciferase Proteins 0.000 claims description 67
- 239000005089 Luciferase Substances 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 48
- 102000001398 Granzyme Human genes 0.000 claims description 41
- 108060005986 Granzyme Proteins 0.000 claims description 41
- 108091033319 polynucleotide Proteins 0.000 claims description 41
- 102000040430 polynucleotide Human genes 0.000 claims description 41
- 239000002157 polynucleotide Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 238000004020 luminiscence type Methods 0.000 claims description 27
- 231100000433 cytotoxic Toxicity 0.000 claims description 22
- 230000001472 cytotoxic effect Effects 0.000 claims description 22
- 108090000397 Caspase 3 Proteins 0.000 claims description 12
- 108090000567 Caspase 7 Proteins 0.000 claims description 12
- 102100029855 Caspase-3 Human genes 0.000 claims description 12
- 102100038902 Caspase-7 Human genes 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 230000003013 cytotoxicity Effects 0.000 claims description 8
- 231100000135 cytotoxicity Toxicity 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 238000012216 screening Methods 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 claims description 2
- 230000033077 cellular process Effects 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 229940121832 Granzyme B inhibitor Drugs 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003384 small molecules Chemical group 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558796P | 2011-11-11 | 2011-11-11 | |
| US61/558,796 | 2011-11-11 | ||
| PCT/US2012/064675 WO2013071237A1 (en) | 2011-11-11 | 2012-11-12 | Mutant protease biosensors with enhanced detection characteristics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501636A JP2015501636A (ja) | 2015-01-19 |
| JP2015501636A5 true JP2015501636A5 (enExample) | 2016-01-14 |
| JP6421977B2 JP6421977B2 (ja) | 2018-11-14 |
Family
ID=47222333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541370A Active JP6421977B2 (ja) | 2011-11-11 | 2012-11-12 | 検出特性を向上させた変異プロテアーゼバイオセンサー |
Country Status (3)
| Country | Link |
|---|---|
| EP (2) | EP3467119B1 (enExample) |
| JP (1) | JP6421977B2 (enExample) |
| WO (1) | WO2013071237A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2541765A1 (en) | 2003-10-10 | 2004-10-01 | Promega Corporation | Luciferase biosensor |
| EP2327768B1 (en) | 2006-04-03 | 2015-09-09 | Promega Corporation | Permuted and nonpermuted luciferase biosensors |
| WO2009142735A2 (en) | 2008-05-19 | 2009-11-26 | Promega Corporation | LUCIFERASE BIOSENSORS FOR cAMP |
| US9290794B2 (en) * | 2010-05-11 | 2016-03-22 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
| US8735559B2 (en) | 2010-05-11 | 2014-05-27 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
| GB202108355D0 (en) * | 2021-06-11 | 2021-07-28 | Univ Edinburgh | Granzyme B detection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602677B1 (en) * | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB9823468D0 (en) * | 1998-10-28 | 1998-12-23 | Secr Defence | Novel enzyme |
| US7879540B1 (en) | 2000-08-24 | 2011-02-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
| US7927871B2 (en) * | 2002-01-29 | 2011-04-19 | Oncoimmunin, Inc. | Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers |
| JP4485470B2 (ja) * | 2002-12-23 | 2010-06-23 | プロメガ コーポレイション | ルシフェラーゼ酵素活性を保護するための方法及びキット |
| CA2541765A1 (en) | 2003-10-10 | 2004-10-01 | Promega Corporation | Luciferase biosensor |
| EP2327768B1 (en) * | 2006-04-03 | 2015-09-09 | Promega Corporation | Permuted and nonpermuted luciferase biosensors |
| US8658777B2 (en) * | 2007-05-09 | 2014-02-25 | The University Of Tokyo | Activated protease indicator |
| US8735559B2 (en) * | 2010-05-11 | 2014-05-27 | Promega Corporation | Mutant protease biosensors with enhanced detection characteristics |
-
2012
- 2012-11-12 EP EP18205893.3A patent/EP3467119B1/en active Active
- 2012-11-12 WO PCT/US2012/064675 patent/WO2013071237A1/en not_active Ceased
- 2012-11-12 JP JP2014541370A patent/JP6421977B2/ja active Active
- 2012-11-12 EP EP12791055.2A patent/EP2776573A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501636A5 (enExample) | ||
| Bielska et al. | Hook is an adapter that coordinates kinesin-3 and dynein cargo attachment on early endosomes | |
| Gjetting et al. | Live imaging of intra-and extracellular pH in plants using pHusion, a novel genetically encoded biosensor | |
| Lürick et al. | Multivalent Rab interactions determine tether-mediated membrane fusion | |
| York et al. | Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance | |
| Wysocki et al. | Novel variants of angiotensin converting enzyme-2 of shorter molecular size to target the kidney renin angiotensin system | |
| Lehmann et al. | Acidosis-induced activation of anion channel SLAH3 in the flooding-related stress response of Arabidopsis | |
| MX387465B (es) | Marcas genéticas de transgenes y métodos de uso. | |
| Nejat et al. | S protein, ACE2 and host cell proteases in SARS-CoV-2 cell entry and infectivity; is soluble ACE2 a two blade sword? A narrative review | |
| van Anken et al. | Specificity in endoplasmic reticulum-stress signaling in yeast entails a step-wise engagement of HAC1 mRNA to clusters of the stress sensor Ire1 | |
| Levytskyy et al. | Metalloproteases of the inner mitochondrial membrane | |
| JP2005507650A (ja) | 新規融合タンパク質及び分子結合に関するアッセイ | |
| Werner et al. | NBR1 is involved in selective pexophagy in filamentous ascomycetes and can be functionally replaced by a tagged version of its human homolog | |
| JP2010537669A5 (enExample) | ||
| Smith et al. | Protein-scaffold directed nanoscale assembly of T cell ligands: artificial antigen presentation with defined valency, density, and ratio | |
| CA2929392A1 (en) | Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through camp pathways | |
| Boucher et al. | Development of a multifunctional tool for drug screening against Plasmodial protein–protein interactions via surface plasmon resonance | |
| Fukutani et al. | The N‐terminal replacement of an olfactory receptor for the development of a yeast‐based biomimetic odor sensor | |
| Chaudhry et al. | Autonomous and in trans functions for the two halves of Srv2/CAP in promoting actin turnover | |
| Chung et al. | The dimeric transmembrane domain of prolyl dipeptidase DPP‐IV contributes to its quaternary structure and enzymatic activities | |
| Xu et al. | N-terminal domain of vacuolar SNARE Vam7p promotes trans-SNARE complex assembly | |
| Hillar et al. | Formation of an antiparallel, intermolecular coiled coil is associated with in vivo dimerization of osmosensor and osmoprotectant transporter ProP in Escherichia coli | |
| Utsugi et al. | Strategies for post-translational control of protein expression and their applications | |
| JP2022528270A5 (enExample) | ||
| Dalton et al. | Olfactory and vomeronasal receptor feedback employ divergent mechanisms of PERK activation |